Jazz Pharmaceuticals (JAZZ) FY2017 results: revenue $1.6 billion, up 8.8% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.6 billion for fiscal 2017, the year ended 31 December 2017, up 8.8% on the year before. Net income was $488 million, up 22.9%, and diluted earnings per share $7.96. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2018.
Revenue
$1.6 billion
+8.8% on the year
FY2010FY2017
Operating margin
32.7%
39.8% a year earlier
FY2010FY2017
Net income
$488 million
+22.9% on the year
FY2010FY2017
Diluted EPS
$7.96
+24.2% on the year
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
1,619
1,488
1,325
+8.8%
Research and development
198
162
135
+22.3%
Selling, general and administrative
544
503
449
+8.2%
Operating income
529
592
508
-10.6%
Operating margin
32.7%
39.8%
38.4%
Interest expense
37.8
27.5
26.5
+37.5%
Pre-tax income
441
532
436
-17.2%
Income tax
-47.7
135
106
Effective tax rate
-10.8%
25.4%
24.4%
Net income
488
397
330
+22.9%
Net margin
30.1%
26.7%
24.9%
Diluted EPS
$7.96
$6.41
$5.23
+24.2%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
693
592
532
+17.0%
Capital expenditure
28.9
9.7
36.0
+198.9%
Free cash flow
664
583
496
+14.0%
Free cash flow margin
41.0%
39.2%
37.4%
Cash from investing
-269
-1,749
-2.3
Cash from financing
-409
541
-214
Depreciation and amortisation
13.1
11.8
9.9
+11.0%
Share-based compensation
107
98.8
91.5
+8.2%
Buybacks
98.8
278
61.6
-64.5%
Diluted shares, weighted
61m
62m
63m
-0.9%
Shares outstanding at period end
60m
60m
61m
+0.1%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
2,713
1,877
1,599
+44.5%
Non-controlling interest
n/a
n/a
0.0
Debt
1,581
2,030
1,188
-22.1%
Other liabilities
830
893
546
-7.1%
Total liabilities and equity
5,124
4,800
3,333
+6.7%
Fixed assets
170
107
85.6
+58.2%
Goodwill
948
894
657
+6.0%
Intangible assets
2,979
3,012
1,186
-1.1%
Securities held for sale or to maturity
601
n/a
n/a
Cash and equivalents
386
366
989
+5.5%
Receivables
224
234
210
-4.3%
Inventory
43.2
34.1
19.5
+27.0%
Other assets
n/a
153
186
Total assets
5,124
4,800
3,333
+6.7%
10-K for the year ended 31 December 2017, filed 27 February 2018: the filing.